Home » Stocks » OTIC

Otonomy, Inc. (OTIC)

Stock Price: $2.56 USD 0.06 (2.40%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
Market Cap 120.56M
Revenue (ttm) 273,000
Net Income (ttm) -44.73M
Shares Out 40.85M
EPS (ttm) -1.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $2.56
Previous Close $2.50
Change ($) 0.06
Change (%) 2.40%
Day's Open 2.50
Day's Range 2.45 - 2.60
Day's Volume 539,885
52-Week Range 1.53 - 6.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

Benzinga - 2 weeks ago

Otonomy Inc (NASDAQ: OTIC) has reported topline data from Phase 3 trial evaluating OTIVIDEX in patients with Ménière's disease. It is an inner ear disorder that causes episodes of vertigo (spi...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

GlobeNewsWire - 3 weeks ago

Conference call and webcast today at 4:30 p.m. ET

GlobeNewsWire - 1 month ago

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

Seeking Alpha - 1 month ago

OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021.

GlobeNewsWire - 2 months ago

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

Zacks Investment Research - 2 months ago

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided u...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

Seeking Alpha - 4 months ago

Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 4 months ago

Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript

Benzinga - 4 months ago

Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results. Quarterly Results Earnings per share were up 33.33% over the past year to ($0.22), which beat the estimate of (...

GlobeNewsWire - 4 months ago

Conference call and webcast today at 4:30 p.m. ET

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

GlobeNewsWire - 5 months ago

SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced ...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announc...

Seeking Alpha - 7 months ago

Otonomy, Inc. (OTIC) CEO David Weber on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Otonomy (OTIC) delivered earnings and revenue surprises of -2.78% and -92.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 7 months ago

Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss

GlobeNewsWire - 7 months ago

Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020

GlobeNewsWire - 7 months ago

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

Zacks Investment Research - 7 months ago

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

GlobeNewsWire - 8 months ago

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

Benzinga - 8 months ago

Otonomy (NASDAQ: OTIC) shares are trading higher on Tuesday. The company reported results from its Phase 1/2 clinical trial of OTO-313 in patients with Tinnitus demonstrated a higher proportio...

GlobeNewsWire - 8 months ago

SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

GlobeNewsWire - 8 months ago

Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET Manageme...

GlobeNewsWire - 8 months ago

Conference call and webcast today at 4:30 p.m. ET

Zacks Investment Research - 8 months ago

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

GlobeNewsWire - 10 months ago

Conference call to review status of clinical trials and timing to results to be held in June Conference call to review status of clinical trials and timing to results to be held in June

GlobeNewsWire - 10 months ago

SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provid...

Seeking Alpha - 1 year ago

Otonomy's (OTIC) CEO David Weber on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Otonomy (OTIC) delivered earnings and revenue surprises of 23.40% and -15.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announce...

GlobeNewsWire - 1 year ago

Three programs with clinical trial results in 2020 including OTIVIDEX™  Phase 3 trial in Ménière’s disease

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Otonomy.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 3rd

Other stocks mentioned: CHRS, IRWD, UFAB
Seeking Alpha - 1 year ago

Otonomy's (OTIC) CEO David Weber on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Initial focus on GJB2, the most common cause of genetic hearing loss in newborns Initial focus on GJB2, the most common cause of genetic hearing loss in newborns

Other stocks mentioned: AGTC

About OTIC

Otonomy, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical tria... [Read more...]

Industry
Biotechnology
IPO Date
Aug 13, 2014
CEO
David Weber
Employees
56
Stock Exchange
NASDAQ
Ticker Symbol
OTIC
Full Company Profile

Financial Performance

In 2020, Otonomy's revenue was $273,000, a decrease of -54.50% compared to the previous year's $600,000. Losses were -$44.73 million, 0.13% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 5.38, which is an increase of 110.16% from the latest price.

Price Target
$5.38
(110.16% upside)
Analyst Consensus: Strong Buy